Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.

We describe in the present paper mutations of the catalytic subunit α of PKA (protein kinase A) that introduce amino acid side chains into the ATP-binding site and progressively transform the pocket to mimic that of Aurora protein kinases. The resultant PKA variants are enzymatically active and exhibit high affinity for ATP site inhibitors that are specific for Aurora kinases. These features make the Aurora-chimaeric PKA a valuable tool for structure-based drug discovery tasks. Analysis of crystal structures of the chimaera reveal the roles for individual amino acid residues in the binding of a variety of inhibitors, offering key insights into selectivity mechanisms. Furthermore, the high affinity for Aurora kinase-specific inhibitors, combined with the favourable crystallizability properties of PKA, allow rapid determination of inhibitor complex structures at an atomic resolution. We demonstrate the utility of the Aurora-chimaeric PKA by measuring binding kinetics for three Aurora kinase-specific inhibitors, and present the X-ray structures of the chimaeric enzyme in complex with VX-680 (MK-0457) and JNJ-7706621 [Aurora kinase/CDK (cyclin-dependent kinase) inhibitor].

[1]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[2]  G. Cheetham,et al.  Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. , 2007, Cancer letters.

[3]  Daniel K. Treiber,et al.  Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. , 2006, Cancer research.

[4]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[5]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[6]  Jaime Prilusky,et al.  Automated analysis of interatomic contacts in proteins , 1999, Bioinform..

[7]  N. Gray,et al.  Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. , 2006, Journal of the American Chemical Society.

[8]  A. Greener,et al.  Site-directed mutagenesis using double-stranded plasmid DNA templates. , 1996, Methods in molecular biology.

[9]  R. Huber,et al.  Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). , 2003, Journal of molecular biology.

[10]  D. Bergstrom,et al.  A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Susan S. Taylor,et al.  Comparative surface geometry of the protein kinase family , 2009, Protein science : a publication of the Protein Society.

[12]  Michael Mortimore,et al.  Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents , 2009 .

[13]  R. Pepperkok,et al.  Intracellular Distribution of Mammalian Protein Kinase a Catalytic Subunit Altered by Conserved Asn2 Deamidation , 2000, The Journal of cell biology.

[14]  R. Engh,et al.  Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase. , 2011, Journal of medicinal chemistry.

[15]  Angela Smallwood,et al.  Modulation of kinase‐inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX‐680 and with TPX2 , 2008, Protein science : a publication of the Protein Society.

[16]  Kaori Sasai,et al.  Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. , 2004, Cell motility and the cytoskeleton.

[17]  Gennady M Verkhivker,et al.  Cancer driver mutations in protein kinase genes. , 2009, Cancer letters.

[18]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[19]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[20]  R. Huber,et al.  The typically disordered N-terminus of PKA can fold as a helix and project the myristoylation site into solution. , 2004, Biochemistry.

[21]  Chi-Ying F. Huang,et al.  The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. , 2009, Journal of hepatology.

[22]  R. Huber,et al.  Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89 , 1996, The Journal of Biological Chemistry.

[23]  Susan S. Taylor,et al.  Crystal structure of the E230Q mutant of cAMP‐dependent protein kinase reveals an unexpected apoenzyme conformation and an extended N‐terminal A helix , 2005, Protein science : a publication of the Protein Society.

[24]  Lynn F. Ten Eyck,et al.  A helix scaffold for the assembly of active protein kinases , 2008, Proceedings of the National Academy of Sciences.

[25]  Lynn F Ten Eyck,et al.  Crystal structure of a cAMP-dependent protein kinase mutant at 1.26A: new insights into the catalytic mechanism. , 2004, Journal of molecular biology.

[26]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[27]  R. Huber,et al.  Phosphorylation and flexibility of cyclic-AMP-dependent protein kinase (PKA) using (31)P NMR spectroscopy. , 2002, Biochemistry.

[28]  R. Huber,et al.  Phosphotransferase and substrate binding mechanism of the cAMP‐dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5‐24). , 1993, The EMBO journal.

[29]  G. Heijne,et al.  Structural Bioinformatics-Based Design of Selective , Irreversible Kinase Inhibitors , 2005 .

[30]  Stefan Bonn,et al.  Structural Analysis of Protein Kinase A Mutants with Rho-kinase Inhibitor Specificity* , 2006, Journal of Biological Chemistry.

[31]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[32]  R. Engh,et al.  VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. , 2011, The journal of physical chemistry. A.

[33]  S. Taylor,et al.  The catalytic subunit of cAMP-dependent protein kinase: prototype for an extended network of communication. , 1999, Progress in biophysics and molecular biology.

[34]  Ian Collins,et al.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.

[35]  D. McRee,et al.  Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[36]  S. Taylor,et al.  Autophosphorylation of the catalytic subunit of cAMP-dependent protein kinase in Escherichia coli. , 1997, Protein engineering.

[37]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[38]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[39]  A. Lochner,et al.  The many faces of H89: a review. , 2006, Cardiovascular drug reviews.

[40]  Ian Collins,et al.  A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. , 2007, Journal of molecular biology.

[41]  K. Vrana,et al.  Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. , 1982, Biochemistry.

[42]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.